Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C
- PMID: 20162613
- DOI: 10.1002/hep.23489
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C
Abstract
25-Hydroxyvitamin D (25[OH]D) can potentially interfere with inflammatory response and fibrogenesis. Its role in disease progression in chronic hepatitis C (CHC) and its relation with histological and sustained virological response (SVR) to therapy are unknown. One hundred ninety-seven patients with biopsy-proven genotype 1 (G1) CHC and 49 healthy subjects matched by age and sex were consecutively evaluated. One hundred sixty-seven patients underwent antiviral therapy with pegylated interferon plus ribavirin. The 25(OH)D serum levels were measured by high-pressure liquid chromatography. Tissue expression of cytochrome (CY) P27A1 and CYP2R1, liver 25-hydroxylating enzymes, were assessed by immunochemistry in 34 patients with CHC, and in eight controls. The 25(OH)D serum levels were significantly lower in CHC than in controls (25.07 +/- 9.92 microg/L versus 43.06 +/- 10.19; P < 0.001). Lower levels of 25(OH)D were independently linked to female sex (P = 0.007) and necroinflammation (P = 0.04) by linear regression analysis. CYP27A1, but not CYP2R1, was directly related to 25(OH)D levels (P = 0.01), and inversely to necroinflammation (P = 0.01). Low 25(OH)D (odds ratio [OR], 0.942; 95% confidence interval [CI], 0.893-0.994) and cholesterol (OR, 0.981; 95%CI, 0.969-0.992) levels, older age (OR, 1.043; 95%CI, 1.002-1.085), high ferritin (OR, 1.003; 95%CI, 1.001-1.005), and necroinflammation (OR, 2.235; 95%CI, 1.014-4.929) were independently associated with severe fibrosis (F3-F4) by multivariate logistic analysis. Seventy patients (41%) achieved SVR. By multivariate analysis, hepatic steatosis (OR, 0.971; 95%CI, 0.944-0.999), lower cholesterol (OR, 1.009; 95% CI, 1.000-1.018), and 25(OH)D levels (OR, 1.039; 95%CI, 1.002-1.077) were independently associated with no SVR.
Conclusion: G1 CHC patients had low 25(OH)D serum levels, possibly because of reduced CYP27A1 expression. Low vitamin D is linked to severe fibrosis and low SVR on interferon (IFN)-based therapy.
Comment in
-
Fibrosis in liver as a predictive marker for hepatitis C virus therapy.Hepatology. 2010 May;51(5):1858; author reply 1858. doi: 10.1002/hep.23629. Hepatology. 2010. PMID: 20432265 No abstract available.
-
Low levels of 25-hydroxyvitamin D(3) in children with biopsy-proven nonalcoholic fatty liver disease.Hepatology. 2010 Jun;51(6):2229; author reply 2230. doi: 10.1002/hep.23724. Hepatology. 2010. PMID: 20513013 No abstract available.
-
Metabolic syndrome and obesity as additional factors that determine clinical response in chronic hepatitis C.Hepatology. 2010 Jun;51(6):2229-30; author reply 2230. doi: 10.1002/hep.23734. Hepatology. 2010. PMID: 20513014 No abstract available.
-
Vitamin D controls T cell activation: implication for causal association between vitamin D deficiency and fibrosis in chronic hepatitis C.Hepatology. 2010 Nov;52(5):1864. doi: 10.1002/hep.23781. Hepatology. 2010. PMID: 20672383 No abstract available.
Similar articles
-
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients.J Viral Hepat. 2013 Jul;20(7):486-93. doi: 10.1111/jvh.12072. Epub 2013 Mar 25. J Viral Hepat. 2013. PMID: 23730842
-
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.J Hepatol. 2013 Mar;58(3):467-72. doi: 10.1016/j.jhep.2012.11.017. Epub 2012 Nov 23. J Hepatol. 2013. PMID: 23183524
-
Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population.Curr HIV Res. 2011 Apr;9(3):186-93. doi: 10.2174/157016211795945269. Curr HIV Res. 2011. PMID: 21585333
-
Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection.Front Biosci (Elite Ed). 2012 Jan 1;4(4):1276-86. doi: 10.2741/e458. Front Biosci (Elite Ed). 2012. PMID: 22201953 Review.
-
Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.Int J Clin Exp Med. 2015 Jul 15;8(7):10284-303. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26379820 Free PMC article. Review.
Cited by
-
Hepatology elsewhere.J Clin Exp Hepatol. 2011 Jun;1(1):49-52. doi: 10.1016/S0973-6883(11)60113-8. Epub 2011 Aug 26. J Clin Exp Hepatol. 2011. PMID: 25755313 Free PMC article. No abstract available.
-
Classical and emerging roles of vitamin D in hepatitis C virus infection.Semin Liver Dis. 2011 Nov;31(4):387-98. doi: 10.1055/s-0031-1297927. Epub 2011 Dec 21. Semin Liver Dis. 2011. PMID: 22189978 Free PMC article. Review.
-
Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.World J Gastroenterol. 2015 May 14;21(18):5647-53. doi: 10.3748/wjg.v21.i18.5647. World J Gastroenterol. 2015. PMID: 25987791 Free PMC article. Clinical Trial.
-
Low vitamin D levels are associated with high viral loads in patients with chronic hepatitis B: a systematic review and meta-analysis.BMC Gastroenterol. 2019 Jun 11;19(1):84. doi: 10.1186/s12876-019-1004-2. BMC Gastroenterol. 2019. PMID: 31185932 Free PMC article.
-
Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis.Intern Emerg Med. 2019 Aug;14(5):753-761. doi: 10.1007/s11739-019-02042-2. Epub 2019 Jan 31. Intern Emerg Med. 2019. PMID: 30706253
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous